<unk>  (brand name Fetzima) is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).
Levomilnacipran
Ciltacabtagene autoleucel
Brexucabtagene autoleucel
Lisocabtagene maraleucel
Milnacipran
Pivhydrazine
Darvadstrocel
Damoctocog alfa pegol